Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

University of Calgary

$140,000.00

Cyp46A1 as a novel therapeutic target in prion diseases

FY 2020-21

Summary
Prion diseases are a group of infectious and incurable neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has been transmitted to humans from cattle. There is no treatment available for prion diseases, therefore, in this study we will apply a novel therapeutic strategy to treat prion diseases. Brain locally synthesizes cholesterol which is a major component of brain cells; however, its excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions, and that the build-up of prions in the brain further increases cholesterol levels in the brain, subsequently facilitating prion formation. Therefore, regulating brain cholesterol levels during prion infection could prevent prion disease. The primary pathway for brain cholesterol elimination is achieved by the brain-specific enzyme, cholesterol 24-hydroxylase (CYP46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. It is of utmost importance to determine the role of Cyp461 in prion diseases. We have collected preliminary data which demonstrate for the first time that the brains of prion infected mice and CJD patients have reduced Cyp46A1 levels. This project will be the first to determine the therapeutic efficacy of the Cyp46A1 activator, Efavirenz (EFV) in prion diseases. EFV is an FDA approved drug which reaches the brain and is currently used for the treatment of HIV patients. Our goal is to test if this drug could be repurposed for treatment of prion diseases. Mice overexpressing human prion will be infected with CJD patients brain homogenates, which will be treated with EFV. Thus, Cyp46A1 is a novel therapeutic target, and its activation through repurposed medications such as EFV is a valuable approach for the treatment of prion diseases.
Program
Banting Postdoctoral Fellowship Program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
436100
Name
Ali Tahir
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Cyp46A1 as a novel therapeutic target in prion diseases
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Brain Cholesterol Metabolism; Cellular Models Of Prion Disease; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Mouse Models Of Human Prion Disease; Neurodegenerative Diseases; Neuroscience; Prion Disease; Repurposed Drug, Efavirenz; Treatment Of Prion Disease
Abstract
Prion diseases are a group of infectious and incurable neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has been transmitted to humans from cattle. There is no treatment available for prion diseases, therefore, in this study we will apply a novel therapeutic strategy to treat prion diseases. Brain locally synthesizes cholesterol which is a major component of brain cells; however, its excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions, and that the build-up of prions in the brain further increases cholesterol levels in the brain, subsequently facilitating prion formation. Therefore, regulating brain cholesterol levels during prion infection could prevent prion disease. The primary pathway for brain cholesterol elimination is achieved by the brain-specific enzyme, cholesterol 24-hydroxylase (CYP46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. It is of utmost importance to determine the role of Cyp461 in prion diseases. We have collected preliminary data which demonstrate for the first time that the brains of prion infected mice and CJD patients have reduced Cyp46A1 levels. This project will be the first to determine the therapeutic efficacy of the Cyp46A1 activator, Efavirenz (EFV) in prion diseases. EFV is an FDA approved drug which reaches the brain and is currently used for the treatment of HIV patients. Our goal is to test if this drug could be repurposed for treatment of prion diseases. Mice overexpressing human prion will be infected with CJD patients brain homogenates, which will be treated with EFV. Thus, Cyp46A1 is a novel therapeutic target, and its activation through repurposed medications such as EFV is a valuable approach for the treatment of prion diseases.
Competitiondate
202010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ali, Tahir
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~
University of Calgary - $140,000 Grant (2020-21) | Canada Spends